# EDGAR Filing Document

**Accession Number:** 0001138723
**File Stem:** 0000950103-25-011114
**Filing Date:** 2025-9
**Character Count:** 62358
**Document Hash:** 3e5f584812afc2325bc064ddc0815f76
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950103-25-011114.hdr.sgml**: 20250902

**ACCESSION NUMBER**: 0000950103-25-011114

**CONFORMED SUBMISSION TYPE**: 424B3

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250902

**DATE AS OF CHANGE**: 20250902

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ACCURAY INC
- **CENTRAL INDEX KEY:** 0001138723
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 208370041
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 424B3
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-288998
- **FILM NUMBER:** 251286687

**BUSINESS ADDRESS:**
- **STREET 1:** 1240 DEMING WAY
- **CITY:** MADISON
- **STATE:** WI
- **ZIP:** 53717
- **BUSINESS PHONE:** 608-824-2800

**MAIL ADDRESS:**
- **STREET 1:** 1240 DEMING WAY
- **CITY:** MADISON
- **STATE:** WI
- **ZIP:** 53717

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-288998

**PROSPECTUS**

**Accuray Incorporated**

**23,428,241 Shares of Common Stock**

This prospectus covers the offer and resale by the selling stockholders (the "Selling Stockholders") identified herein, from time to time in one or more offerings, of up to 23,428,241 shares of our common stock, par value $0.001 per share, which consist of (i) an aggregate of 17,180,710 shares of our common stock issuable upon exercise of warrants (the "Premium Warrants") that we issued to the Selling Stockholders pursuant to the Financing Agreement (as defined below) and (ii) an aggregate of 6,247,531 shares of our common stock issuable upon exercise of warrants (the "Penny Warrants" and, together with the Premium Warrants, the "Warrants") that we issued to the Selling Stockholders pursuant to the Financing Agreement.

On June 6, 2025, we entered into a senior secured credit agreement (the "Financing Agreement") by and among Accuray Incorporated, as borrower, certain lenders from time to time party thereto, TCW Asset Management Company LLC, as collateral agent and administrative agent for the lenders, and certain other parties thereto. Pursuant to such Financing Agreement, we issued to the Selling Stockholders the Premium Warrants at an exercise price of $1.68 per share and the Penny Warrants at an exercise price of $0.01 per share. The exercise period for the Premium Warrants begins on December 7, 2025 and ends on June 6, 2032, and the exercise period for the Penny Warrants began on June 6, 2025 and ends on June 6, 2032. Pursuant to the terms of the Warrants, we agreed to provide customary shelf registration rights to the Selling Stockholders covering the resale of the shares of our common stock issuable upon exercise of the Warrants.

We are not selling any shares of our common stock under this prospectus and will not receive any proceeds from the sale of shares of common stock by the Selling Stockholders. However, we will receive proceeds from any cash exercise of the Warrants. We have agreed to pay certain expenses related to the registration of the offer and sale of the shares of common stock pursuant to the registration statement of which this prospectus forms a part. The Selling Stockholders will bear all commissions and discounts, if any, attributable to the sale of the shares.

Our common stock is listed on The Nasdaq Global Select Market under the symbol "ARAY." On August 29, 2025, the last reported sale price of our common stock on The Nasdaq Global Select Market was $1.52 per share.

We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read the entire prospectus (including the documents incorporated by reference herein) and any amendments or supplements carefully before you make your investment decision.

**Investing in our common stock involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading "Risk Factors" beginning on page 1 of this prospectus, and under similar headings in the documents that are incorporated by reference into this prospectus.** 

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.** 

**The date of this prospectus is September 2, 2025.**

**table of contents**

<u>Page</u>

---

| | |
|:---|:---|
| [About this Prospectus](#a_001) | [1](#a_001) |
| [Trademarks](#a_002) | [1](#a_002) |
| [Cautionary Note Regarding Forward-Looking Statements](#a_003) | [2](#a_003) |
| [Prospectus Summary](#a_004) | [3](#a_004) |
| [Risk Factors](#a_005) | [4](#a_005) |
| [Use of Proceeds](#a_006) | [5](#a_006) |
| [Description of Securities](#a_007) | [6](#a_007) |
| [Selling Stockholders](#a_008) | [10](#a_008) |
| [Plan of Distribution](#a_009) | [13](#a_009) |
| [Legal Matters](#a_010) | [16](#a_010) |
| [Experts](#a_011) | [16](#a_011) |
| [Where You Can Find More Information](#a_012) | [16](#a_012) |
| [Information Incorporated by Reference](#a_013) | [16](#a_013) |

---

i

[**Table of Contents**](#toc)

**About this Prospectus**

This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission (the "SEC"), under the Securities Act of 1933, as amended ("Securities Act"). Under this shelf registration process, the Selling Stockholders named in this prospectus may offer or sell shares of our common stock in one or more offerings from time to time. Each time the Selling Stockholders named in this prospectus (or in any supplement to this prospectus) sells shares of our common stock under the registration statement of which this prospectus is a part, such Selling Stockholders must provide a copy of this prospectus and any applicable prospectus supplement, to a potential purchaser, as required by law.

In certain circumstances, a prospectus supplement may add, update or change information included in this prospectus. Any statement contained in this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in such prospectus supplement modifies or supersedes such statement. You should read both this prospectus and any prospectus supplement, including all documents incorporated herein or therein by reference, together with additional information described under "*Where You Can Find More Information*" and *"Information Incorporated by Reference*" beginning on page 13 of this prospectus.

Neither we nor the Selling Stockholders have authorized any other person to provide you with information other than the information contained or incorporated by reference in this prospectus and any accompanying prospectus supplement. If anyone provides you with different or inconsistent information, you should not rely on it. Neither we nor any of the Selling Stockholders will make an offer to sell our common stock in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus and any prospectus supplement is accurate as of the date on its respective cover, and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, unless we indicate otherwise. Our business, financial condition, results of operations and prospects may have changed since those dates.

Unless the context otherwise indicates, the terms "Accuray," "Company," "Registrant," "we," "us," and "our" as used in this prospectus refer to Accuray Incorporated and our subsidiaries, and the term "common stock" refers to our common stock, par value $0.001 per share. The phrase "this prospectus" refers to this prospectus and any applicable prospectus supplement, unless the context otherwise requires.

**Trademarks**

This document or the documents incorporated by reference herein contain references to trademarks and service marks belonging to us or other entities. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the <sup>®</sup> or™ symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend the use or display of other companies' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of it by, any other companies.

[**Table of Contents**](#toc)

**Cautionary Note Regarding Forward-Looking Statements**

This prospectus and certain information incorporated herein by reference contain forward-looking statements within the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements included or incorporated by reference in this registration statement, other than statements that are purely historical, are forward-looking statements. Words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "may," "will be," "will continue," "will likely result," and similar expressions also identify forward-looking statements. Those statements appear in this prospectus and the documents incorporated herein and therein by reference, particularly in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Business," and include statements regarding the intent, belief or current expectations of our management that are subject to known and unknown risks, uncertainties and assumptions, and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. We refer you to the risks discussed in our other filings with the Securities and Exchange Commission incorporated by reference herein, which identify important risks and uncertainties that could cause actual results to differ materially from those contained in the forward-looking statements. The discussion of risks and uncertainties set forth in those filings should not be construed as exhaustive and should be read with the other cautionary statements in this prospectus.

Our expectations, beliefs, objectives, intentions and strategies regarding future results are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from results contemplated by our forward-looking statements. We assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of the filing of this prospectus.

[**Table of Contents**](#toc)

**Prospectus summary**

*This summary highlights selected information and does not contain all of the information that is important to you. This summary is qualified in its entirety by the more detailed information included or incorporated by reference in this prospectus. Before making your investment decision with respect to our securities, you should carefully read this entire prospectus, any applicable prospectus supplement and the documents referred to in "Where You Can Find More Information".*

**The Company**

We are a radiation therapy company that develops, manufactures, sells and supports market-changing solutions that are designed to deliver radiation treatments for even the most complex cases, while making commonly treatable cases even more straightforward, to meet the full spectrum of patient needs. We believe in comparison to conventional linear accelerators, our treatment delivery, planning, and data management solutions provide better accuracy, flexibility, and control; fewer treatments with shorter treatment times; and the technology to expand beyond cancer, making it easier for clinical teams around the world to provide treatments that help patients get back to living their lives, faster.

Our innovative technologies, the CyberKnife<sup>®</sup> and TomoTherapy<sup>®</sup> platforms, including the Radixact<sup>®</sup> System, our next generation TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery ("SRS"), stereotactic body radiation therapy ("SBRT"), intensity modulated radiation therapy ("IMRT"), image-guided radiation therapy ("IGRT"), and adaptive radiation therapy ("ART"). The CyberKnife and TomoTherapy platforms have complementary clinical applications with the same goal: to empower our customers to deliver the most precise and accurate treatments while still minimizing dose to healthy tissue, helping to reduce the risk of side effects that may impact patients' quality of life. Each of these systems serves patient populations treated by the same medical specialty, radiation oncology, with advanced capabilities. The CyberKnife platform is also used by neurosurgeons specializing in radiosurgery to treat patients with tumors in the brain and spine, and neurologic and/or endocrine disorders. In addition to these products, we also provide services which include post-contract customer support (warranty period services and post-warranty services), installation services, training, and other professional services.

**Corporate Information**

We were incorporated in California in 1990 and commenced operations in 1992. We reincorporated in Delaware in 2007. Our principal offices in the United States are located in Madison, Wisconsin and Santa Clara, California, and our telephone number is (608) 824-2800. Our main corporate website address is *www.accuray.com*. The information on our website is not a part of nor incorporated by reference in this prospectus.

[**Table of Contents**](#toc)

**Risk Factors**

An investment in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks and uncertainties described under "Part I. Item 1A. Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2025, which is incorporated by reference in this prospectus, together with all of the other information contained in this prospectus and the documents incorporated by reference herein. If any of these risks actually occur, our business, operating results and financial condition could be materially and adversely impacted, the market price of our common stock could decline and you could lose all or part of your investment. The risks and uncertainties described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations and financial results and the value of our common stock.

[**Table of Contents**](#toc)

**Use of Proceeds**

We will not receive any proceeds from the sale of shares of our common stock by the Selling Stockholders. However, we will receive proceeds from any cash exercise of the Warrants. There can be no assurance that any of the Warrants will be exercised by the Selling Stockholders or that they will exercise the Warrants for cash instead of using the cashless exercise feature. We intend to use the net proceeds, if any, from any cash exercise of the Warrants for general corporate purposes.

[**Table of Contents**](#toc)

**Description of Securities**

The following summary describes our securities and the material provisions of our amended and restated certificate of incorporation, our amended and restated bylaws, and the applicable provisions of the General Corporation Law of the State of Delaware (the "DGCL"). This summary does not purport to be complete and is qualified in its entirety by the provisions of our amended and restated certificate of incorporation, our amended and restated bylaws and the other documents described in this section, copies of which have been filed with the SEC and are referenced in the exhibits to our registration statement, of which this prospectus forms a part.

**General** 

Our amended and restated certificate of incorporation authorizes us to issue up to 200,000,000 shares of common stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001 par value per share. As of June 30, 2025, we had approximately 112,643,852 shares of common stock outstanding.

***Dividend Rights***

Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available at the times and in the amounts that our board of directors may determine.

***Voting Rights***

Each holder of our common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of the stockholders. Cumulative voting for the election of directors is not provided for in our amended and restated certificate of incorporation, which means that the holders of a majority of the shares voted can elect all of the directors then standing for election.

***No Preemptive or Similar Rights***

Our common stock is not entitled to preemptive rights and is not subject to conversion or redemption. There are no sinking fund provisions applicable to our common stock.

***Right to Receive Liquidation Distributions***

Upon our dissolution or liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders are distributable ratably among the holders of our common stock, subject to the preferential rights and payment of liquidation preferences, if any, on any outstanding shares of preferred stock.

**Anti-Takeover Provisions** 

***Certificate of Incorporation and Bylaws***

Our amended and restated certificate of incorporation provides for our board of directors to be divided into three classes, with staggered three-year terms. Only one class of directors is elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the shares of common stock outstanding is able to elect all of our directors. Our amended and restated certificate of incorporation and amended and restated bylaws provide that all stockholder action must be effected at a duly called meeting of stockholders and not by a consent in writing, and that only our chairperson of the board of directors, chief executive officer, president, secretary or a majority of the authorized number of directors may call a special meeting of stockholders.

Our amended and restated certificate of incorporation requires a 66<sup>2</sup>/3% stockholder vote for the amendment, repeal or modification of certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws relating to the classification of our board of directors, the requirement that stockholder actions be effected at a duly called meeting, and the designated parties entitled to call a special meeting of the stockholders. The combination of the classification of our board of directors, the lack of cumulative voting and the 66<sup>2</sup>/3%

[**Table of Contents**](#toc)

stockholder voting requirements will make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control.

These provisions may have the effect of deterring hostile takeovers or delaying changes in our control or management. These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of us. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they also may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts. Such provisions may also have the effect of preventing changes in our management.

***Section 203 of the Delaware General Corporation Law***

We are subject to Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:

&nbsp;&nbsp;&nbsp;&nbsp;· before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted
in the stockholder becoming an interested holder;

&nbsp;&nbsp;&nbsp;&nbsp;· upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder
owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining
the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by persons
who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially
whether shares held subject to the plan will be tendered in a tender or exchange offer; or

&nbsp;&nbsp;&nbsp;&nbsp;· on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting
of the stockholders, and not by written consent, by the affirmative vote of at least 66<sup>2</sup>/3% of the outstanding voting stock
that is not owned by the interested stockholder.

In general, Section 203 defines business combination to include the following:

&nbsp;&nbsp;&nbsp;&nbsp;· any merger or consolidation involving the corporation and the interested stockholder;

&nbsp;&nbsp;&nbsp;&nbsp;· any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;

&nbsp;&nbsp;&nbsp;&nbsp;· subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation
to the interested stockholder;

&nbsp;&nbsp;&nbsp;&nbsp;· any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series
of the corporation beneficially owned by the interested stockholder; or

&nbsp;&nbsp;&nbsp;&nbsp;· the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by
or through the corporation.

In general, Section 203 defines an "interested stockholder" as an entity or person who, together with the person's affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.

[**Table of Contents**](#toc)

**Limitation of Liability; Indemnification**

As permitted by Section 102(b)(7) of the DGCL, our amended and restated certificate of incorporation contains provisions that limit the liability of its directors for monetary damages to the fullest extent permitted by Delaware law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for any breach of the director's duty of loyalty to us or our stockholders, acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, unlawful payment of dividends or unlawful stock repurchases or redemptions; and any transaction from which the director derived an improper personal benefit.

Our amended and restated certificate of incorporation provides that we may indemnify to the fullest extent permitted by law any person made or threatened to be made a party to an action or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that he, his testator or intestate is or was a director, officer, employee or agent of us or any predecessor of ours, or serves or served at any other enterprise as a director, officer, employee or agent at our request or the request any of our predecessors.

If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director, then the liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our amended and restated certificate of incorporation does not eliminate a director's duty of care and, in appropriate circumstances, equitable remedies, such as injunctive or other forms of non-monetary relief, remain available under Delaware law. This provision also does not affect a director's responsibilities under any other laws, such as the federal securities laws or other state or federal laws.

Our bylaws provide that we shall indemnify and hold harmless, to the fullest extent permitted by the DGCL as it presently exists or may hereafter be amended, any director or officer of ours who was or is made or is threatened to be made a party or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was a director, officer, employee or agent of ours or is or was serving at our request as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or non-profit entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses reasonably incurred by such person in connection with any such action, suit or proceeding.

**Choice of Forum**

Our bylaws provide that, unless we consent, the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty owed by any of our directors, officers, stockholders, employees or agents to us or our stockholders; any action asserting a claim against us or any of our directors, officers, stockholders, employees or agents arising out of or relating to any provision of the DGCL or our amended and restated certificate of incorporation or our bylaws; or any action asserting a claim against us or any of our directors, officers, stockholders, employees or agents that is governed by the internal affairs doctrine; *provided*, *however*, that, in the event that the Court of Chancery of the State of Delaware lacks subject matter jurisdiction over any such action or proceeding, the sole and exclusive forum for such action or proceeding shall be another state or federal court located within the State of Delaware, in each such case, unless the Court of Chancery (or such other state or federal court located within the State of Delaware, as applicable) has dismissed a prior action by the same plaintiff asserting the same claims because such court lacked personal jurisdiction over an indispensable party named as a defendant therein.

**Warrants**

The following table sets forth information about outstanding warrants to purchase shares of our common stock, as of June 30, 2025.

[**Table of Contents**](#toc)

---

| | | | |
|:---|:---|:---|:---|
| **Warrants Exercisable for common stock**  | **Shares of Common Stock Issuable Upon Exercise of the Warrants**  | **Exercise Price Per Share**  | **Exercise Period**  |
| Penny Warrants held by the Selling Stockholders | 6247531 | $0.01 | June 6, 2025 – June 6, 2032 |
| Premium Warrants held by the Selling Stockholders | 17180710 | $1.68 | December 7, 2025 – June 6, 2032 |

---

On June 6, 2025, we issued to certain lenders party to the Financing Agreement (i) the Premium Warrants to purchase 17,180,710 shares of common stock, which warrants are exercisable on and after December 7, 2025 and expire on June 6, 2032 and have an exercise price of $1.68 per share, subject to certain adjustments and (ii) the Penny Warrants to purchase 6,247,531 shares of common stock, which warrants are exercisable on and after June 6, 2025 and expire on June 6, 2032 and have an exercise price of $0.01 per share.

The Warrants have certain anti-dilution protection provisions, including price protection anti-dilution protection in the event that we sell stock at a price below $1.00 in the case of the Penny Warrants and $1.25 in the case of the Premium Warrants. We agreed to issue the Warrants in connection with, and to induce the lenders to enter into, the Financing Agreement.

The terms of the Warrants provide that we will, among other things, prepare and file with the SEC a registration statement covering the resale of the shares underlying the Warrants. The registration statement of which this prospectus is a part has been filed by us in satisfaction of our obligations under the Warrants to file such registration statement. We have also agreed to use commercially reasonable efforts to keep the registration statement of which this prospectus is a part continuously effective, supplemented and amended as required by the Securities Act, in order to permit this prospectus to be usable by the Selling Stockholders for a period from the date the registration statement becomes effective to, and including, the date upon which all registrable securities have been sold and no longer subject to restrictions on transfer or the securities no longer constitute registrable securities (whichever is earlier).

The foregoing summary of the terms and conditions of the Warrants does not purport to be complete and is qualified in its entirety by reference to the Form of Penny Warrants and Form of Premium Warrants that are attached as exhibits to the registration statement of which this prospectus forms a part.

**Listing** 

Our common stock is listed on The Nasdaq Stock Market LLC under the symbol "ARAY."

**Transfer Agent and Registrar** 

The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.

[**Table of Contents**](#toc)

**Selling Stockholders**

This prospectus covers the offering for resale from time to time, in one or more offerings, of up to 23,428,241 shares of our common stock, consisting of (i) 17,180,710 shares of our common stock issuable upon exercise of the Premium Warrants and (ii) 6,247,531 shares of common stock issuable upon exercise of the Penny Warrants by the Selling Stockholders. The term "Selling Stockholders" includes the stockholders listed below and their permitted transferees who may acquire shares from a Selling Stockholder after the date of this prospectus. Information concerning the Selling Stockholders may change after the date of this prospectus and changed information will be presented in a supplement to this prospectus if and when required.

The table below sets forth the following information, as of June 30, 2025: (i) the name of each Selling Stockholder, (ii) the number of shares of common stock beneficially owned by each Selling Stockholder, (iii) the number of shares of common stock offered by each Selling Stockholder hereunder, (iv) the number of shares of common stock beneficially owned by each Selling Stockholder following the completion of this offering (assuming each Selling Stockholder sells all of the shares of our common stock covered by this prospectus), and (v) the percentage of common stock beneficially owned by each Selling Stockholder following the completion of this offering (assuming each Selling Stockholder sells all of the shares of our common stock covered by this prospectus), based on 112,643,852 shares of our common stock outstanding as of June 30, 2025.

The Selling Stockholders are not making any representation that any shares of common stock covered by this prospectus will be offered for sale. Because each Selling Stockholder may dispose of all, none or some portion of the shares of common stock covered by this prospectus, no estimate can be given as to the number of shares that will be beneficially owned by a Selling Stockholder upon termination of this offering. In addition, the Selling Stockholders may have sold, transferred or otherwise disposed of their shares of common stock in transactions exempt from the registration requirements of the Securities Act after the date on which the information in the table is presented. For purposes of the table below, however, we have assumed that after termination of this offering, none of the shares of common stock registered for resale under this prospectus will be beneficially owned by the Selling Stockholders, and we have further assumed that the Selling Stockholders will not acquire beneficial ownership of any additional shares of common stock during this offering.

The following table is prepared based on information provided to us by the Selling Stockholders. Except as may be described below, none of the Selling Stockholders has had any position, office or other material relationship with us or any of our predecessors or affiliates within the past three years. In addition, based on information provided to us, none of the Selling Stockholders that are affiliates of broker-dealers, if any, purchased the shares of our common stock outside the ordinary course of business or, at the time of their acquisition of such shares, had any agreements, understandings or arrangements with any other persons, directly or indirectly, to dispose of the shares. Information concerning the Selling Stockholders may change from time to time, and any changed information will be set forth in supplements to this prospectus to the extent required.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name of Selling Stockholder** | **Shares of Common Stock Beneficially Owned Before this Offering (1)** | **Percentage of Shares of Common Stock Beneficially Owned Before this Offering** | **Shares of Common Stock Offered by this Prospectus (1)** | **Shares of Common Stock Beneficially Owned After this Offering** | **Percentage of Shares of Common Stock Beneficially Owned After this Offering** |
| First Trust Alternative Opportunities Fund (2) | 3611854 | 3.21% | 3611854 | 0 | 0% |
| First Trust Private Credit Fund (3) | 585706 | 0.52% | 585706 | 0 | 0% |
| First Trust Enhanced Private Credit Fund (4) | 488088 | 0.43% | 488088 | 0 | 0% |
| Asilia Credit Fund, LP (5) | 3123765 | 2.77% | 3123765 | 0 | 0% |
| Walnut Capital Fund I, LP (6) | 780941 | 0.69% | 780941 | 0 | 0% |
| Nationwide Mutual Insurance Company (7) | 2928530 | 2.60% | 2928530 | 0 | 0% |
| TCW Rescue Financing Fund II LP (8) | 11079719 | 9.84% | 11079719 | 0 | 0% |
| West Virginia Direct Lending LLC (9) | 829638 | 0.74% | 829638 | 0 | 0% |
| Total | 23428141 | 20.80% | 23428241 | 0 | 0% |

---

[**Table of Contents**](#toc)

(1) Includes shares issuable to the Selling Stockholders upon exercise of the outstanding Warrants.

(2) First Trust Alternative Opportunities Fund ("FTAOF") is the direct holder of the
Premium Warrant and Penny Warrant pursuant to which the shares reported may be issued, which includes (a) 2,648,693 shares of common stock
under a Premium Warrant issued by the Company to FTAOF on June 6, 2025, which Premium Warrant is exercisable on and after six months and
one day after June 6, 2025, expires on June 6, 2032 and has an exercise price of $1.68 per share of common stock, subject to certain adjustments,
and (b) 963,161 shares of common stock under a Penny Warrant issued by the Company to FTAOF on June 6, 2025. First Trust Capital Management
LP ("FTCM") is the investment advisor to FTAOF. Michael Peck, CEO of FTCM, and Chad Eisenberg, COO of FTCM share voting and
dispositive power over the 3,611,854 shares of common stock issuable upon exercise of the Warrants held by FTAOF. The address of FTAOF
is 225 W. Wacker Drive, Suite 2160, Chicago, IL 60606. FTAOF acts as lender in principal amount of $21.6 million to the Company pursuant
to the Financing Agreement. The foregoing reference to the Financing Agreement does not purport to be complete and is subject to, and
qualified in its entirety by, the full text of the Financing Agreement, a copy of which will be filed as an exhibit to the Company's
Annual Report on Form 10-K for the year ending June 30, 2025.

(3) First Trust Private Credit Fund ("FTPCF") is the direct holder of the Premium Warrant
and Penny Warrant pursuant to which the shares reported may be issued, which includes (a) 429,518 shares of common stock under a Premium
Warrant issued by the Company to FTPCF on June 6, 2025, which Premium Warrant is exercisable on and after six months and one day after
June 6, 2025, expires on June 6, 2032 and has an exercise price of $1.68 per share of common stock, subject to certain adjustments, and
(b) 156,188 shares of common stock under a Penny Warrant issued by the Company to FTPCF on June 6, 2025. First Trust Capital Management
LP ("FTCM") is the investment advisor to FTPCF. Michael Peck, CEO of FTCM, and Chad Eisenberg, COO of FTCM share voting and
dispositive power over the 585,706 shares of common stock issuable upon exercise of the Warrants held by FTPCF. The address of FTPCF is
225 W. Wacker Drive, Suite 2160, Chicago, IL 60606. FTPCF acts as lender in principal amount of $3.5 million to the Company pursuant to
the Financing Agreement. The foregoing reference to the Financing Agreement does not purport to be complete and is subject to, and qualified
in its entirety by, the full text of the Financing Agreement, a copy of which will be filed as an exhibit to the Company's Annual
Report on Form 10-K for the year ending June 30, 2025 .

(4) First Trust Enhanced Private Credit Fund ("FTEPCF") is the direct holder of the
Premium Warrant and Penny Warrant pursuant to which the shares reported may be issued, which includes (a) 357,931 shares of common stock
under a Premium Warrant issued by the Company to FTEPCF on June 6, 2025, which Premium Warrant is exercisable on and after six months
and one day after June 6, 2025, expires on June 6, 2032 and has an exercise price of $1.68 per share of common stock, subject to certain
adjustments, and (b) 130,157 shares of common stock under a Penny Warrant issued by the Company to FTEPCF on June 6, 2025. First Trust
Capital Management First Trust Capital Management LP ("FTCM") is the investment advisor to FTEPCF. Michael Peck, CEO of FTCM,
and Chad Eisenberg, COO of FTCM share voting and dispositive power over the 488,088 shares of common stock issuable upon exercise of the
Warrants held by FTEPCF. The address of FTEPCF is 225 W. Wacker Drive, Suite 2160, Chicago, IL 60606. FTEPCF acts as lender in principal
amount of $2.9 million to the Company pursuant to the Financing Agreement. The foregoing reference to the Financing Agreement does not
purport to be complete and is subject to, and qualified in its entirety by, the full text of the Financing Agreement, a copy of which
will be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ending June 30, 2025 .

(5) Asilia Credit Fund, LP ("Asilia") is the direct holder of the Premium Warrant and
Penny Warrant pursuant to which the shares reported may be issued, which includes (a) 2,290,761 shares of common stock under a Premium
Warrant issued by the Company to Asilia on June 6, 2025, which Premium Warrant is exercisable on and after six months and one day after
June 6, 2025, expires on June 6, 2032 and has an exercise price of $1.68 per share of common stock, subject to certain adjustments, and
(b) 833,004 shares of common stock under a Penny Warrant issued by the Company to Asilia on June 6, 2025. Asilia is managed by K. Austin
Read and Jonathan S. Gardner. K. Austin Read and Jonathan S. Gardner share voting and dispositive power over the 3,123,765 shares of common
stock issuable upon exercise of the Warrants held by Asilia. The address of Asilia is 2250 S West Temple St, Salt Lake City, UT 84115.
Asilia acts as lender in principal amount of $18.7 million to the Company pursuant to the Financing Agreement. The foregoing reference
to the Financing Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Financing
Agreement, a copy of which will be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ending June 30,
2025 .

(6) Walnut Capital Fund I, LP ("Walnut") is the direct holder of the Premium Warrant
and Penny Warrant pursuant to which the shares reported may be issued, which includes (a) 572,590 shares of common stock under a Premium
Warrant issued by the Company to Walnut on June 6, 2025, which Premium Warrant is exercisable on and after six months and one day after
June 6, 2025, expires on June 6, 2032 and has an exercise price of $1.68 per share of common stock, subject to certain adjustments, and
(b) 208,251 shares of common stock under a Penny Warrant issued by the Company to Walnut on June 6, 2025. Walnut is managed by Michael
S. Chang. Michael S. Chang holds sole voting and dispositive power over the 780,841 shares of common stock issuable upon exercise of the
Warrants held by Walnut. The address of Walnut is 453 S Spring St., Ste 400, Los Angeles, CA, 90013. Walnut acts as lender in principal
amount of $4.7 million to the Company pursuant to the Financing Agreement. The foregoing reference to the Financing Agreement does not
purport to be complete and is subject to, and qualified in its entirety by, the full text of the Financing Agreement, a copy of which
will be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ending June 30, 2025 .

(7) Nationwide Mutual Insurance Company ("Nationwide") is the direct holder of the Premium
Warrant and Penny Warrant pursuant to which the shares reported may be issued, which includes (a) 2,147,589 shares of common stock under
a Premium Warrant issued by the Company to Nationwide on June 6, 2025, which Premium Warrant is exercisable on and after six months and
one day after June 6, 2025, expires on June 6, 2032 and has an exercise price of $1.68 per share of common stock, subject to certain adjustments,
and (b) 780,941 shares of common stock under a Penny Warrant issued by the Company to Nationwide on June 6, 2025. The Chief Investment
Officer of Nationwide and his authorized delegates each have voting and dispositive power over 2,928,530 shares of common stock issuable
upon exercise of Warrants held by Nationwide. The address of Nationwide is One Nationwide Plaza, Columbus, Ohio 43215. Nationwide acts
as lender in principal amount of $17.5 million to the Company pursuant to the Financing Agreement. The foregoing reference to the Financing
Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Financing Agreement,
a copy of which will be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ending June 30, 2025 .

[**Table of Contents**](#toc)

(8) TCW Rescue Financing Fund II LP ("TCW Rescue Financing") is the direct holder of
the Premium Warrant and Penny Warrant pursuant to which the shares reported may be issued, which includes (a) 8,125,127 shares of common
stock under a Premium Warrant issued by the Company to TCW Rescue Financing on June 6, 2025, which Premium Warrant is exercisable on and
after six months and one day after June 6, 2025, expires on June 6, 2032 and has an exercise price of $1.68 per share of common stock,
subject to certain adjustments, and (b) 2,954,592 shares of common stock under a Penny Warrant issued by the Company to TCW Rescue Financing
on June 6, 2025. TCW Rescue Financing is an indirect subsidiary of The TCW Group, Inc. ("TCW Group"). TCW Group
and its direct and indirect subsidiaries collectively constitute The TCW Group, Inc. business unit (the "TCW Business Unit").
The TCW Business Unit is primarily engaged in the provision of investment management services. The TCW Business Unit is managed separately
and operated independently. The TCW Business Unit has shared voting and dispositive power over 11,909,357 shares of common stock, which
includes the shares described in this footnote and in footnote 9 below. The address of TCW Rescue Financing, TCW Group and the TCW Business
Unit is 515 South Flower Street, Los Angeles, CA 90071. Affiliates of TCW Group act as collateral agent and lenders in principal amount
of $140 million to the Company pursuant to the Financing Agreement. In addition, TCW Asset Management Company LLC ("TCW Asset Management"),
an affiliate of TCW Group, is party to the Governance Agreement, dated as of June 6, 2025 (the "Governance Agreement"), pursuant
to which TCW Asset Management has the right to appoint one director of the Company. Each agreement referenced above is qualified in its
entirety by reference to the Financing Agreement and Governance Agreement attached as exhibits to the registration statement of which
this prospectus forms a part, and the Financing Agreement, a copy of which will be filed as an exhibit to the Company's Annual Report
on Form 10-K for the year ending June 30, 2025, as applicable.

(9) West Virginia Direct Lending LLC ("WV Direct Lending") is the direct holder of the
Premium Warrant and Penny Warrant pursuant to which the shares reported may be issued, which includes (a) 608,401 shares of common stock
under a Premium Warrant issued by the Company to WV Direct Lending on June 6, 2025, which Premium Warrant is exercisable on and after
six months and one day after June 6, 2025, expires on June 6, 2032 and has an exercise price of $1.68 per share of common stock, subject
to certain adjustments, and (b) 221,237 shares of common stock under a Penny Warrant issued by the Company to WV Direct Lending on June
6, 2025. WV Direct Lending's sole investment advisor is an indirect subsidiary of TCW Group. TCW Group and its direct and indirect
subsidiaries collectively constitute the TCW Business Unit. The TCW Business Unit has shared voting and dispositive power over 11,909,357
shares of common stock, which includes the shares described in this footnote and in footnote 8 above. The address of TCW Direct Lending
is 515 South Flower Street, Los Angeles, CA 90071.

[**Table of Contents**](#toc)

**Plan of Distribution**

The Selling Stockholders, which as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests in shares of common stock received after the date of this prospectus from the Selling Stockholders as a gift, pledge, partnership or other distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock covered hereby on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.

The Selling Stockholders may use any one or more of the following methods when disposing of the shares or interests therein:

&nbsp;&nbsp;&nbsp;&nbsp;· on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale;

&nbsp;&nbsp;&nbsp;&nbsp;· in the over-the-counter market;

&nbsp;&nbsp;&nbsp;&nbsp;· in transactions otherwise than on these exchanges or systems or in the over-the-counter market;

&nbsp;&nbsp;&nbsp;&nbsp;· ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

&nbsp;&nbsp;&nbsp;&nbsp;· block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block
as principal to facilitate the transaction;

&nbsp;&nbsp;&nbsp;&nbsp;· purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

&nbsp;&nbsp;&nbsp;&nbsp;· an exchange distribution in accordance with the rules of the applicable exchange;

&nbsp;&nbsp;&nbsp;&nbsp;· privately negotiated transactions;

&nbsp;&nbsp;&nbsp;&nbsp;· through agents;

&nbsp;&nbsp;&nbsp;&nbsp;· through one or more underwriters in a public offering on a firm commitment or best-efforts basis;

&nbsp;&nbsp;&nbsp;&nbsp;· through the settlement of short sales (including short sales "against the box"), in each case subject to compliance with
the Securities Act and other applicable laws;

&nbsp;&nbsp;&nbsp;&nbsp;· through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

&nbsp;&nbsp;&nbsp;&nbsp;· broker-dealers may agree with the Selling Stockholders to sell a specified number of such shares at a stipulated price per share;

&nbsp;&nbsp;&nbsp;&nbsp;· in other ways not involving market makers or established trading markets;

&nbsp;&nbsp;&nbsp;&nbsp;· by pledge to secure debts and other obligations;

&nbsp;&nbsp;&nbsp;&nbsp;· a combination of any such methods of sale; and

&nbsp;&nbsp;&nbsp;&nbsp;· any other method permitted pursuant to applicable law.

The Selling Stockholders may also sell shares under Rule 144 under the Securities Act, if available, rather than under this prospectus, provided that they meet the criteria and conform to the requirements of these provisions.

[**Table of Contents**](#toc)

The Selling Stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if the Selling Stockholders default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424 or other applicable provision of the Securities Act amending the list of Selling Stockholders to include the pledgee, transferee or other successor-in-interest as a Selling Stockholder under this prospectus. The Selling Stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors-in-interest will be the selling beneficial owners for purposes of this prospectus.

In connection with the sale or other disposition of our common stock or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The Selling Stockholders may also sell shares of our common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

The aggregate proceeds to the Selling Stockholders from the sale or other disposition of the common stock covered by this prospectus will be the price at which the shares of common stock are sold or otherwise disposed of, less discounts or commissions, if any. The Selling Stockholders reserve the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds from this offering. However, we will receive proceeds from the exercise of the Warrants if they are exercised for cash by a holder thereof.

The Selling Stockholders and any underwriters, broker-dealers or agents that are involved in selling the common stock or interests therein may be deemed to be "underwriters" within the meaning of Section 2(a)(11) of the Securities Act. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. The maximum amount of any compensation to be received by any Financial Industry Regulatory Authority member will not be greater than an amount that is considered fair and reasonable for the sale of any securities being registered. The Selling Stockholders have informed us that they do not as of the date hereof have any agreement or understanding, directly or indirectly, with any person to distribute the common stock. If a Selling Stockholder is deemed to be an "underwriter" within the meaning of the Securities Act, it will be subject to the prospectus delivery requirements of the Securities Act.

To the extent required, the shares of our common stock to be sold, the name of the Selling Stockholders, the respective purchase prices and public offering prices, the names of any agents, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement of which this prospectus is a part.

In order to comply with the securities laws of some states, if applicable, the shares of our common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states shares of our common stock may not be sold unless they have been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.

The Selling Stockholders and any other person participating in such distribution will be subject to applicable provisions under the Exchange Act and the rules and regulations thereunder, including, without limitation, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the shares of common stock by the Selling Stockholders and any other participating person. In addition, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the Selling Stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The Selling Stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.

[**Table of Contents**](#toc)

We have agreed to indemnify the Selling Stockholders against liabilities in relation to the registration of the shares offered by this prospectus and certain liabilities under the Securities Act or any other similar federal or state securities laws.

We have agreed to pay the applicable filing fee with respect to the registration of these shares and any subsequent shelf registration, and pay our own direct costs, including the professional fees of our own counsel and independent registered accountants. The Selling Stockholders shall bear the cost of their own counsel, other advisors and any broker or other intermediary involved in any resale, including all applicable underwriting discounts and commissions, brokers' commissions and stock transfer taxes, if any, on the shares sold by the Selling Stockholders in any such resale.

We have agreed to use commercially reasonable efforts to keep the registration statement of which this prospectus is a part continuously effective, supplemented and amended as required by the Securities Act, in order to permit this prospectus to be usable by the Selling Stockholders for a period from the date the registration statement becomes effective to, and including, the date upon which all registrable securities have been sold and no longer subject to restrictions on transfer or the securities no longer constitute registrable securities (whichever is earlier).

Once sold under the registration statement of which this prospectus is a part, the shares of common stock will be freely tradable in the hands of persons other than our affiliates.

[**Table of Contents**](#toc)

**Legal Matters**

Davis Polk & Wardwell LLP, Redwood City, California will pass upon the validity of the shares of common stock offered by this prospectus.

**Experts**

The financial statements and management's assessment of the effectiveness of internal control over financial reporting incorporated by reference in this prospectus and elsewhere in the registration statement have been so incorporated by reference in reliance upon the reports of Grant Thornton LLP, independent registered public accountants, upon the authority of said firm as experts in accounting and auditing.

**Where You Can Find More Information**

We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information about issuers, including Accuray Incorporated, who file electronically with the SEC. The address of that website is http://www.sec.gov.

Our SEC filings are also available on our website: *www.accuray.com*. Except for documents filed with the SEC and incorporated by reference into this prospectus, no information contained in, or that can be accessed through, our website is to be considered part of this prospectus.

**Information Incorporated by Reference**

The rules of the SEC allow us to incorporate by reference into this prospectus the information we file with the SEC. This means that we are disclosing important information to you by referring to other documents. The information incorporated by reference is considered to be part of this prospectus, except for any information superseded by information contained directly in this prospectus. We incorporate by reference the documents listed below (other than any portions thereof, which under the Exchange Act, and applicable SEC rules, are not deemed "filed" under the Exchange Act):

&nbsp;&nbsp;&nbsp;&nbsp;· our Annual Report on Form 10-K for the year ended June 30, 2025, filed with the SEC on [August 28, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001138723/000119312525191242/aray-20250630.htm) ;

&nbsp;&nbsp;&nbsp;&nbsp;· our Current Report on Form 8-K filed with the SEC on [August 22, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001138723/000119312525186407/aray-20250819.htm) ; and

&nbsp;&nbsp;&nbsp;&nbsp;· the description of our common stock contained in our Registration Statement on Form 8-A filed with the Commission on [February 7, 2007](https://www.sec.gov/Archives/edgar/data/1138723/000110465907007766/a07-3619_18a12b.htm) , including any subsequently filed amendments and reports updating that description.

We also incorporate by reference into this prospectus all future reports and other documents (other than the Current Reports on Form 8-K or portions thereof that are "furnished" under Item 2.02 or Item 7.01 of Form 8-K) that we file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i) after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, and (ii) on and after the date of this prospectus but prior to the termination or completion of the offering of shares of common stock under this prospectus.

Any statement contained in a document incorporated by reference in this prospectus shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or in any other subsequently filed document that is also incorporated by reference in this prospectus modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.

[**Table of Contents**](#toc)

We will furnish without charge to you, on written or oral request, a copy of any or all of the documents incorporated by reference in this prospectus, including exhibits to these documents. You should direct any requests for documents to Accuray Incorporated, 1240 Deming Way, Madison, WI 53717.

You also may access these filings on our website at *www.accuray.com*. We do not incorporate the information on our website into this prospectus or any supplement to this prospectus and you should not consider any information on, or that can be accessed through, our website as part of this prospectus or any supplement to this prospectus (other than those filings with the SEC that we specifically incorporate by reference into this prospectus or any supplement to this prospectus).

**23,428,241 Shares of Common Stock**

**Accuray Incorporated**